Search

A recent report from Ibn Sina University Hospital discusses the findings of a case study on pediatric patients with familial Mediterranean fever (FMF), a genetic disorder common in the Mediterranean area. The study focuses on a rare case of a child with a heterozygous mutation in the MEVF gene, which led to chronic renal failure. The researchers emphasize the importance of early diagnosis in heterozygous children to prevent fatal complications and unnecessary treatments. The study highlights the need for further research in this area. [Extracted from the article]

A recent study conducted in Paris, France, examined the transition from pediatric to adult care for individuals with autoinflammatory diseases. The study found that effective transition programs are necessary to ensure continuity of care and disease management. The research included 111 patients and found that those who underwent a transition had earlier and more regular follow-up in adulthood compared to those who did not transition. The type of transition did not significantly impact disease control during follow-up. The study emphasizes the importance of collaborative transition programs in autoinflammatory diseases. [Extracted from the article]

A study conducted by Usak University in Turkey examined the impact of gene mutation diversity and disease severity on the physical capacity and quality of life in children and adolescents with Familial Mediterranean Fever (FMF). The study included 80 participants diagnosed with FMF and used various assessments to evaluate their physical capacity and quality of life. The results showed that gene mutation did not significantly affect physical capacity and quality of life, but disease severity did have an impact on quality of life. The researchers concluded that encouraging physical activity and providing psychosocial support could improve the quality of life for individuals with FMF. [Extracted from the article]

This article discusses a novel method for assessing the pathogenicity of mutations on protein functions, specifically focusing on Pyrin protein variants associated with familial Mediterranean fever (FMF). The method uses mutual information (MI) to measure the correlation between residue motions and changes affecting the phenotype. The study demonstrates the utility of MI profile shifts in assessing the effects of mutations on protein stability, function, and disease phenotype. The paper also emphasizes the importance of negative MI shifts as indicators of severe functional effects and explores potential compensatory mechanisms indicated by positive MI shifts. The study provides insights into the molecular mechanisms underlying the pathogenesis of FMF and offers a framework for identifying potential therapeutic targets based on MI profile changes induced by mutations. [Extracted from the article]

A recent study conducted by Istanbul University-Cerrahpasa has shed light on familial Mediterranean fever (FMF), a common autoinflammatory disease. The primary treatment for FMF is colchicine, but 5-10% of patients do not respond to this medication and are considered colchicine resistant. The study examined severity scores, damage indices, and definitions of colchicine resistance, highlighting the need for a new severity score that integrates the definition of colchicine resistance. This research provides valuable insights into the management of FMF and may be of interest to those studying hereditary autoinflammatory diseases and conditions. [Extracted from the article]

A recent study conducted by researchers at Celal Bayar University School of Medicine in Manisa, Turkey, examined the quality of life (QoL) in children with Familial Mediterranean Fever (FMF) and their parents' perception of their QoL. The study found that the severity of FMF is inversely correlated with QoL scores, with mild cases having the highest scores. Various factors such as disease severity, treatment adherence, healthcare utilization, genetic mutations, family income, and maternal age at birth significantly impact the perceived QoL in FMF patients. The study concluded that FMF significantly impacts children's daily activities, academic performance, and family functioning, and healthcare providers should be aware of these QoL changes in managing FMF patients. [Extracted from the article]

A recent study conducted by researchers at the University of Bonn in Germany explores the relationship between chronic inflammatory diseases and amyloidosis, a group of diseases characterized by the deposition of insoluble amyloid fibrils in tissues. The study specifically focuses on amyloid A (AA) amyloidosis, which is closely associated with conditions such as rheumatoid arthritis, Familial Mediterranean Fever, Crohn's disease, and chronic infections. The researchers found that the inflammasome adaptor ASC plays a significant role in the development of AA amyloidosis and suggests potential immunotherapy options for treating the disease. This research provides valuable insights into the pathogenesis of amyloidosis and offers potential avenues for future treatment approaches. [Extracted from the article]

A report from the Gazi University Faculty of Medicine in Ankara, Turkey, discusses the clinical associations of the E148Q variant in patients with vasculitis. The study aimed to investigate the diagnoses and disease courses of patients with E148Q heterozygosity to assist physicians in interpreting the variant. Among the patients with the E148Q variant, the most common diagnoses were healthy, IgA vasculitis, Familial Mediterranean Fever (FMF), and Periodic fever, Aphtous stomatitis, Pharyngitis, Adenitis (PFAPA). The study found that the E148Q variant may amplify inflammation and modify disease courses, and patients with typical FMF episodes should receive colchicine treatment. However, further research is needed to determine the treatment-modifying role of the E148Q variant in PFAPA. [Extracted from the article]

A report from Hacettepe University in Ankara, Turkey discusses the advancements in pediatric rheumatology over the past 25 years. The concept of autoinflammation, particularly in relation to familial Mediterranean fever, has been a major development in the field. Genetic studies have revealed the complexity of heritability in inflammation, and the application of other 'omics' technologies has generated a large dataset that can be used for the development of new therapies and precision medicine. The COVID-19 pandemic has also sparked investigations into the link between viral infections and inflammatory responses in children. [Extracted from the article]

Researchers at Bangladesh University of Engineering and Technology have developed a game model to explore the dynamics of newborn vaccination. The model incorporates potential periodic behavior and aims to create an engaging simulation that emphasizes the importance of timely infant vaccinations. The results show that a higher efficacy in a newborn vaccine program can potentially eradicate the disease, but higher effectiveness and cost may deter vaccination. The research offers solutions and closed-form expressions that may exhibit periodic or non-periodic behavior, aiding efforts to prevent recurrent outbreaks. [Extracted from the article]

The article offers information on the association between the M694V homozygous mutation in familial Mediterranean fever (FMF) and eosinophilic intestinal inflammation. Topics discussed include the clinical and histological features observed in pediatric FMF patients; the prevalence of endoscopic findings in these patients; and the need for specialized gastroenterological evaluation for those with specific intestinal symptoms.

A recent study conducted at Cairo University examined the relationship between metabolic syndrome and Familial Mediterranean Fever (FMF) in Egyptian children. FMF is an inherited autoinflammatory disease, while metabolic syndrome is a cluster of risk factors including insulin resistance, obesity, dyslipidemia, and hypertension. The study found that while none of the FMF patients met the criteria for metabolic syndrome, there was a higher frequency of insulin resistance among FMF patients compared to the control group. This suggests that children with FMF may be at a higher risk of developing metabolic syndrome later in life. [Extracted from the article]

A 30-year-old woman with familial Mediterranean fever (FMF) was diagnosed with minimal change disease (MCD) and treated with methylprednisolone. However, after 16 weeks of treatment, remission was not achieved, indicating a lack of efficacy. The woman was then switched to ciclosporin and gradually tapered off methylprednisolone, resulting in decreased proteinuria and remission during the 4-month follow-up period. This case report highlights the challenges of treating MCD and the need for alternative therapies in steroid-resistant cases. [Extracted from the article]

A 30-year-old woman with familial Mediterranean fever (FMF) and minimal change disease (MCD) did not respond to treatment with colchicine and methylprednisolone. She also exhibited non-compliance with colchicine treatment. After being admitted to the hospital for extensive edema, she was diagnosed with secondary amyloidosis and MCD related to FMF. Her edema was controlled with diuretic therapy, and she was also taking ramipril. Despite 16 weeks of treatment with methylprednisolone, remission was not achieved, and she was diagnosed with steroid-resistant MCD. She continued taking colchicine throughout the treatment but did not respond to it. After considering other causes of nephrotic syndrome, she was started on ciclosporin and methylprednisolone was gradually tapered. At the time of follow-up, remission was achieved. [Extracted from the article]

A recent report from Cairo University discusses research on Familial Mediterranean Fever (FMF), the most prevalent autoinflammatory disease. The study aimed to evaluate the serum prolidase level in children with FMF and compare it to healthy children, as well as investigate its correlation with FMF disease criteria and inflammatory markers. The results showed that FMF patients had lower serum prolidase levels during attack-free periods compared to the control group. However, the prolidase level was not correlated with disease severity or predictive of subclinical inflammation. Further studies are needed to understand the role of serum prolidase in FMF children. [Extracted from the article]

A study conducted at Schneider Children's Medical Center in Israel examined the association between inflammatory bowel diseases (IBD) and familial Mediterranean fever (FMF), two auto-inflammatory diseases with similar features. The study found that FMF is more prevalent in IBD patients, particularly in those with Crohn's disease (CD). The diagnosis of FMF often precedes the diagnosis of IBD, and in patients with ulcerative colitis (UC), FMF may be associated with a more severe disease course. The study utilized data from a nationwide cohort and was supported by the Leona M. and Harry B. Helmsley Charitable Trust. [Extracted from the article]

A recent study conducted at Cairo University explored the levels of serum uric acid and glomerular filtration rate (GFR) in children with Familial Mediterranean Fever (FMF) during the attack-free period. FMF is an inherited periodic fever syndrome caused by a mutation in the MEFV gene. The study found that uric acid levels were within the normal range for age among children with FMF during the attack-free periods and were not predictive of impaired GFR or the presence of albuminuria. However, a subset of FMF patients did show impaired GFR and microalbuminuria during the attack-free periods, despite having normal kidney function. Further research is needed to understand the risk factors and the value of GFR and microalbuminuria in monitoring children with FMF. [Extracted from the article]

A report from Tokyo Medical University discusses a case of chronic kidney disease (CKD) in a pediatric patient who experienced refractory periodic vomiting and hypertension. The symptoms of CKD can significantly impact the quality of life for patients, especially children, and may cause growth retardation. The patient in this case study was successfully treated with a combination therapy of AST-120 and angiotensin-converting enzyme inhibitor-I (ACE-I), which alleviated the vomiting and reduced blood pressure. The study also suggests that specific chemokines may serve as diagnostic or prognostic biomarkers for CKD. [Extracted from the article]

A recent study conducted at Cairo University examined the levels of serum calprotectin (CLP) in children with Familial Mediterranean Fever (FMF) during attack-free periods. The study included 35 children with FMF and 35 children in a control group. The results showed that serum CLP levels were elevated in some children with FMF during attack-free periods, but there were no significant correlations between CLP levels and FMF clinical presentations or disease severity scores. The researchers concluded that further studies are needed to determine the diagnostic accuracy and prognostic ability of CLP in FMF. [Extracted from the article]

A systematic review conducted by researchers at Centre hospitalier de Versailles in France explored the potential use of tocilizumab (TCZ) in the treatment of familial Mediterranean fever (FMF). FMF is an autoinflammatory disease characterized by recurrent fever and serosal inflammation. While colchicine is the primary treatment, approximately 10% of FMF patients do not respond to it, necessitating alternative therapies. The review found that TCZ may be beneficial for FMF patients with established renal AA amyloidosis and resistance to colchicine and interleukin 1 inhibitors. However, more research is needed to fully understand the safety and efficacy of TCZ in FMF. [Extracted from the article]

A recent study conducted by researchers at Cairo University examined the frequency of neurological manifestations among Egyptian children with Familial Mediterranean Fever (FMF). FMF is an auto-inflammatory periodic disorder caused by mutations in the Mediterranean fever gene. The study found that neurological symptoms such as headache, paresthesia, convulsions, tremors, breath-holding attacks, and syncope were reported among the participants. Headache and paresthesia were the most common symptoms, particularly among patients with compound heterozygous mutations, severe disease scores, and poor compliance with colchicine treatment. The researchers emphasize the importance of disease control and adherence to colchicine to manage these neurological manifestations. [Extracted from the article]

In a multicentre retrospective study, six children with familial Mediterranean fever (FMF) were treated with colchicine but showed a lack of efficacy. The children had different genetic variants associated with FMF, and some of them received canakinumab therapy as an alternative. This study highlights the need for further research on treatment options for FMF in children who do not respond to colchicine. [Extracted from the article]

A recent report from researchers at the Siberian Branch of the Russian Academy of Sciences provides new insights into Familial Mediterranean Fever (FMF), a systemic autoinflammatory disorder caused by mutations in the MEFV gene. The study focused on the generation of induced pluripotent stem cells (iPSCs) from a patient with FMF carrying a specific mutation in the MEFV gene. The researchers found that the morphology of macrophages derived from these iPSCs differed significantly from those derived from iPSCs of a healthy donor. This research contributes to a better understanding of the molecular genetic mechanisms underlying FMF. [Extracted from the article]

A recent study conducted by researchers at the University of Siena in Italy explored the relationship between Familial Mediterranean Fever (FMF) and the risk of cancer development. FMF is a severe systemic inflammatory condition that affects the innate immune system. The study found that FMF patients had a reduced risk of developing malignant neoplasms compared to patients with fibromyalgia, Still's disease, and Behçet's disease. However, when cancer did occur in FMF patients, it was more frequent in those with a severe disease phenotype and colchicine-resistant disease. The study identified several clinical variables associated with cancer development in FMF patients, including age at disease onset, number of attacks per year, and the use of certain medications. [Extracted from the article]

A recent study conducted in Cairo, Egypt, examined the expression levels of microRNAs (miR-148b and miR-17) and Caspase-1 gene in pediatric patients with Familial Mediterranean Fever (FMF). The study included 25 FMF cases and 25 healthy individuals. The results showed that miR-17 was significantly upregulated in FMF cases, while miR-148b was significantly downregulated. Additionally, Caspase-1 expression was found to be upregulated in FMF cases. These findings suggest that miR-17 and miR-148b could serve as potential biomarkers for FMF, and Caspase-1 may be a future therapeutic target for alleviating inflammation in FMF patients. Further research on larger cohorts is needed to better understand the role of microRNAs in FMF pathogenesis and severity. [Extracted from the article]

A recent study conducted at Friedrich-Alexander-University Erlangen-Nurnberg (FAU) in Germany examined the use of IL-1 inhibitors in the treatment of Familial Mediterranean Fever (FMF). The study found that a subset of FMF patients with a more severe phenotype, earlier disease onset, and M694V homozygosity may require IL-1 inhibitor treatment despite the overall effectiveness of colchicine. The study identified colchicine resistance, intolerance, and complications such as amyloidosis as indications for IL-1 inhibitor therapy. This research provides valuable insights into the clinical characteristics and treatment indications for FMF patients requiring IL-1 inhibition therapy. [Extracted from the article]

A recent study conducted by researchers at Tokyo Medical and Dental University Hospital focused on Cryopyrin-Associated Periodic Syndromes (CAPS), a genetic disorder characterized by chronic inflammation throughout the body. The study specifically examined a case of a newborn with CAPS who experienced severe neonatal asphyxia due to a ruptured umbilical cord associated with severe funisitis. The researchers found that histopathologic examination of the placenta and umbilical cord can provide important insights into the intrauterine onset of inflammation in newborns with CAPS. The study highlights the potential complications related to the placenta and umbilical cord in births with a genetic predisposition to CAPS. [Extracted from the article]

A recent study conducted by researchers from Necmettin Erbakan University examined the morphological, fractal, and textural features of the mandibular bone in patients with Familial Mediterranean Fever (FMF) compared to healthy controls. The study included 50 FMF patients and 50 age- and sex-matched healthy controls. The researchers used digital panoramic images to evaluate the mandibular cortex and applied the box-counting method to calculate the fractal dimension. The results showed that there were no significant differences in the morphological, fractal, and textural features of the mandibular bone between FMF patients and healthy controls. This study provides valuable insights into the impact of FMF on bone health. [Extracted from the article]

A recent study conducted in Ankara, Turkey, focused on familial Mediterranean fever (FMF), a condition characterized by febrile polyserositis attacks. The researchers specifically examined adolescent FMF patients with menstruation-associated attacks and proposed a management algorithm. The study found that patients with menstruation-associated FMF attacks had different characteristics compared to those without such attacks, including a higher rate of dysmenorrhea and higher attack frequency. The interventions for menstruation-associated attacks included various treatments such as colchicine, anti-inflammatory drugs, and glucocorticoids. The study concluded that on-demand therapies could be beneficial in managing these attacks. [Extracted from the article]

A recent study conducted by Istanbul University-Cerrahpasa in Turkey examined the cardiac functions of children with Familial Mediterranean Fever (FMF) during acute attacks and remission periods. FMF is an autosomal recessive autoinflammatory disease characterized by recurring serosal inflammation. The study found that FMF patients experience cardiac abnormalities during active inflammation, particularly in the left ventricle and right ventricle. The findings highlight the importance of monitoring cardiac functions in FMF patients and emphasize the need for long-term cardiac function monitoring in the management of the disease. [Extracted from the article]

A recent study conducted by researchers at Medical University in Sofia, Bulgaria, explores the topic of invasive cervical resorption (ICR) in dentistry. ICR is a relatively uncommon and complex phenomenon that can be caused by both local and systemic factors. The study presents a case report of a patient with an "idiopathic" Class 3 ICR lesion in the maxillary central incisor, providing insights into the surgical management and long-term follow-up results. The researchers highlight the importance of choosing the appropriate repair material for ICR lesions, especially in patients with concomitant systemic disorders. The study also raises questions about the potential connection between ICR and a rare genetic disease called Familial Mediterranean fever. [Extracted from the article]

A recent study conducted by Pamukkale University in Denizli, Turkey, examined the cardiac functions of children with Familial Mediterranean Fever (FMF) during the attack-free period. The study included 75 FMF patients and 50 healthy children as a control group. The researchers used various methods such as electrocardiography, Holter monitoring, and echocardiography to evaluate cardiac involvement. The findings indicated that cardiac involvement can exist in FMF patients even during nonattack periods. This research provides valuable insights into the understanding of FMF and its potential impact on cardiac health. [Extracted from the article]

A preprint abstract from biorxiv.org discusses a novel method for assessing the pathogenicity of mutations on protein functions. The method focuses on the role of mutual information (MI) as a measure to quantify the correlation between residue motions or fluctuations. The study applies this method to Pyrin protein variants associated with familial Mediterranean fever (FMF) and demonstrates its utility in assessing the effects of mutations on protein stability, function, and disease phenotype. The paper also highlights the importance of negative MI shifts as indicators of severe effects and explores potential compensatory mechanisms indicated by positive MI shifts. The study emphasizes the need for comprehensive analysis considering genetic, environmental, and stochastic factors and offers insights into the molecular mechanisms underlying disease progression and potential therapeutic targets. [Extracted from the article]

A recent study conducted by Tel Aviv University in Israel compared the effectiveness and safety of two different treatment strategies for children with colchicine-resistant familial Mediterranean fever (crFMF). The study focused on the use of canakinumab, a monoclonal antibody that targets interleukin-1 beta. The first treatment strategy involved monthly subcutaneous injections of canakinumab, while the second strategy, known as the "canakinumab on demand" (COD) policy, allowed for wider intervals between drug administrations. The study found that both treatment strategies resulted in a significant reduction in FMF attacks, with similar efficacy and safety. However, the COD policy required a lower accumulated dose of canakinumab, making it less immunosuppressive and less expensive. [Extracted from the article]

A 44-year-old woman with familial Mediterranean fever (FMF) experienced a lack of efficacy while being treated with colchicine. She had been suffering from recurrent episodes of high fever, abdominal pain, and back pain for the past 2 years. After starting colchicine treatment, her symptoms improved, but she continued to experience low-grade fever, persistent back pain, and difficulty raising her left arm. It was determined that she had colchicine-resistant FMF, and she was subsequently treated with canakinumab, which resulted in the elimination of her symptoms. [Extracted from the article]

A recent study conducted at Uludag University in Bursa, Turkey, explored the use of blood-based biomarkers to predict the risk of amyloidosis and the severity of familial Mediterranean fever (FMF). The researchers focused on a marker called the pan-immune-inflammation value (PIV), which consists of four subsets of blood cells. They found that PIV, along with other markers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and red blood cell distribution width, could be useful in predicting both amyloidosis and moderate-to-severe disease in FMF patients. This research provides valuable insights into the potential use of biomarkers for diagnosing and managing FMF. [Extracted from the article]

A recent study conducted by researchers from the University of Montpellier in France focuses on Familial Mediterranean Fever (FMF), an inherited autoinflammatory disease. FMF primarily affects populations of Mediterranean origin and is characterized by recurrent fever. The disease is caused by mutations in the MEFV gene, which encodes pyrin, a component of the inflammasome. The study highlights new genetic mechanisms and phenotypes associated with FMF, including atypical autoinflammatory syndromes and a rare dermatological disease called pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND). The findings contribute to a better understanding of FMF and its genetic basis. [Extracted from the article]

A recent study conducted by Istanbul University-Cerrahpasa aimed to identify the triggering factors for familial Mediterranean fever (FMF) attacks and analyze their relationship with the Mediterranean fever gene mutation status. The study found that psychological stress was the most frequent triggering factor for FMF attacks, followed by cold exposure and humidity. The research suggests that identifying these trigger factors can lead to better preventive measures and personalized therapies to decrease FMF attacks. Managing psychological stress and avoiding physical factors such as cold exposure and fatigue can significantly reduce the number of FMF attacks experienced by patients. [Extracted from the article]

A 47-year-old man developed pneumonia while being treated with prednisone for Familial Mediterranean fever syndrome. The man had a history of recurrent skin and soft tissue infections, as well as recurrent pneumonias. He was referred to a clinic for an immunodeficiency workup and was diagnosed with Familial Mediterranean fever syndrome. He initially received colchicine, which provided some relief, but later developed pneumonia as a result of prednisone treatment. He was then treated with azathioprine, which helped decrease his symptoms. At the time of the case report, he continued to have ongoing ear infections and mastoiditis. [Extracted from the article]

A study conducted at Menoufia University in Egypt examined the levels of serum endocan, asymmetric dimethylarginine (ADMA), and lipid profiles in children with Familial Mediterranean Fever (FMF) during the attack-free period. The researchers found that FMF patients had significantly higher levels of serum endocan, ADMA, low-density lipoprotein cholesterol, triglycerides, and certain atherogenic indices compared to healthy controls. The study suggests that serum ADMA and lipid profile could potentially serve as markers for endothelial dysfunction and increased cardiovascular risk in FMF patients. This research provides valuable insights into the understanding of FMF and its associated risks. [Extracted from the article]

A retrospective study involving 37 patients with familial Mediterranean fever (FMF) reported a case of a patient who developed a COVID-19 infection while being treated with canakinumab for FMF. The patient received canakinumab every two months and was subsequently hospitalized due to the COVID-19 infection. The study attributed the infection to canakinumab, but further details about the patient's age, sex, dosage, outcome, and duration of treatment were not provided. [Extracted from the article]

A 20-year-old man experienced drug tolerance and a rebound effect after discontinuing anakinra, a medication used to treat vasculitic lesions and familial Mediterranean fever. The man had previously been diagnosed with familial Mediterranean fever and received colchicine, which improved his symptoms. He later developed vasculopathic lesions and was treated with prednisolone and azathioprine, achieving remission. However, he developed anemia and macrocytosis, leading to the discontinuation of azathioprine. After starting anakinra, his vasculitic lesions were temporarily controlled, but they reemerged after discontinuing the medication. He was then diagnosed with a deficiency of adenosine deaminase 2 and received infliximab and colchicine, which improved his lesions. [Extracted from the article]

A recent report from researchers at Friedrich-Alexander University in Erlangen, Germany, highlights the challenges faced by patients with familial Mediterranean fever (FMF) and other autoinflammatory diseases. The study collected data from 1043 patients from 52 countries and found that both children and adults experienced delays in diagnosis, misdiagnosis, and symptoms such as pain and fatigue. The research emphasizes the need to raise awareness of these diseases in the medical community to improve patient care and quality of life. The full report can be accessed for free through the Journal of Clinical Medicine. [Extracted from the article]

A recent study conducted by Cairo University has found that combining extra virgin olive oil (EVOO) with colchicine can be effective in treating colchicine-resistant familial Mediterranean fever (CRFMF) in patients. The study showed that the frequency of episodes and inflammatory indicators significantly decreased after a three-month course of daily EVOO treatment with colchicine. In addition, there was an overall improvement in the quality of life of CRFMF patients. The research concluded that EVOO, when paired with the tolerated dosage of colchicine, had a positive impact on the management of CRFMF without any negative side effects. [Extracted from the article]

A recent study conducted by Firat University examined the cardiac functions and pericardial thickness changes in patients with familial Mediterranean fever (FMF). The study included 99 FMF patients and a control group of 24 healthy children. The results showed that there was no significant relationship between genetic abnormalities and pericardial thickness in FMF patients. However, pericardial thickness was found to be greater in FMF patients compared to those without FMF. The study concluded that cardiac inflammation continues in children with FMF, even if they are asymptomatic, and recommended monitoring cardiac functions, including the pericardium, as part of long-term follow-up for FMF patients. [Extracted from the article]

A recent study conducted at Uludag University examined the quality and reliability of English-language YouTube videos as a source of information for patients with familial Mediterranean fever (FMF). The researchers evaluated the relevance and accuracy of the most viewed videos on YouTube related to FMF and assessed their educational value using the Global Quality Scale (GQS). Out of the 59 videos reviewed, 72.9% were of high quality, 16.9% were of medium quality, and 10.2% were of low quality. The study concluded that YouTube is a valuable resource for high-quality videos that can supplement the educational material for FMF patients, and healthcare providers should guide their patients to reliable video sources. [Extracted from the article]

A recent study conducted at Istanbul Medipol University examined the pain characteristics and imagery ability in patients with Familial Mediterranean Fever (FMF). The researchers found that patients with FMF had lower imagery scores compared to the control group. Additionally, patients who had catastrophic thoughts showed higher scores in imagery ability, suggesting that their attention processes to their bodies may be affected. The study concludes that further research is needed to confirm these findings. [Extracted from the article]

A recent study conducted at Sheba Medical Center in Israel has found that patients with Familial Mediterranean Fever (FMF), a genetic disorder characterized by recurrent episodes of fever and inflammation, may be at risk for long-term joint damage that may require surgical joint replacement. The study analyzed data from over 9,000 FMF patients and found that 1.2% of them underwent arthroplasty, compared to 0.7% of the control group. FMF patients of North African origin were found to have a significantly higher risk of arthroplasty. While joint damage is relatively uncommon in FMF patients, it occurs almost twice as frequently as in the general population. [Extracted from the article]

A recent report discusses the genetic basis and clinical features of Familial Mediterranean Fever (FMF), an inherited autoinflammatory disease that is prevalent in Middle Eastern and Mediterranean populations. The disease is primarily caused by defects in innate immunity and is characterized by recurrent episodes of fever, abdominal, chest, or joint pain, and elevated levels of serum amyloid A. Diagnosis is made using specific criteria and confirmed through genetic testing. Treatment involves the use of colchicine to prevent attacks and complications such as renal amyloidosis. Genetic testing helps in identifying specific mutations and tailoring treatment plans for individual patients. [Extracted from the article]